The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of eribulin mesylate (EM) in patients with advanced breast cancer: The Royal Marsden experience.
Eirini Thanopoulou
Honoraria - Eisai
Claudia Omarini
No relevant relationships to disclose
Belinda Yeo
No relevant relationships to disclose
Mark Allen
No relevant relationships to disclose
Marina Parton
No relevant relationships to disclose
Nicholas C. Turner
No relevant relationships to disclose
Mary E.R. O'Brien
No relevant relationships to disclose
Stephen R. D. Johnston
No relevant relationships to disclose
Ian E. Smith
No relevant relationships to disclose